Predictors of functional benefit of hepatitis C therapy in a ‘real-life’ cohort

Table 1 Baseline characteristics of the study population

Demographics	Value
Age (yr)	59 ± 10 (27-83)
Male gender	133 (67)
HCV genotype
1a	47 (23)
1b	100 (50)
1 (no confirmed subtype)	9 (5)
2	7 (4)
3	30 (15)
4	6 (3)
Viral load 106 (IU/mL)	2.04 ± 3.46 (0.01-34.50)
Treatment history
Treatment naive	86 (43)
Treatment experienced	113 (57)
Protease inhibitor experienced	8 (4)
Liver/renal status
Platelets (103/μL)	116 ± 61 (26-341)
Total bilirubin (mg/dL)	1.4 ± 0.9 (0.2-5.7)
INR	1.34 ± 0.78 (0.40-5.70)
Creatinine (mg/dL)	0.80 ± 0.22 (0.43-1.96)
TE score (kPa)1	24.5 ± 12.5 (5.5-75)
Average MELD score	9 ± 3 (6-23)
MELD score
< 10	130 (65)
10-15	59 (30)
> 15	10 (5)
Child-Pugh score
A	152 (76)
B	40 (20)
C	7 (4)

Data are expressed as n (%) or means ± SD (range).

¹Data available for 112 patients.

Table 2 Therapy regime and treatment duration

Therapy regime	Treatment duration (wk)	GT 1	GT 2	GT 3	GT 4
SOF + RBV	12	2 (1)	5 (3)
SOF + RBV	24	11 (5)		18 (9)
SOF + LDV	12				1 (1)
SOF + LDV + RBV	12	73 (36)			2 (1)
SOF + LDV + RBV	24	14 (6)		3 (2)
SOF + DCV	12	2 (1)		1 (1)
SOF + DCV	24	19 (9)
SOF + DCV + RBV	12	3 (2)	2 (1)	1 (1)
SOF + DCV + RBV	24	3 (2)		7 (3)
SOF + SMV	12	13 (6)			3 (2)
SOF + SMV + RBV	12	2 (1)
PTV/r + OMV + DSV	12	8 (4)
PTV/r + OMV + DSV + RBV	12	6 (3)

Data are expressed as number of patients for each therapy regime (percent of total patients). GT: Genotype, SOF: Sofosbuvir; RBV: Ribavirin; LDV: Ledipasvir; DCV: Daclatasvir; SMV: Simeprevir; PTV/r: Paritaprevir/ritonavir; OMV: Ombitasvir; DSV: Dasabuvir.

Table 3 Predictors of functional benefit (MELD score decrease) following antiviral therapy based on patient baseline characteristics

Baseline parameters	MELD decrease		P value (univariable)	P value (multivariable3)	OR (95%CI)
	Yes (n = 78, 44%)	No (n = 101, 56%)
Age (yr)	59 ± 9	59 ± 9	0.9781	0.815	0.996 (0.961-1.032)
Child-Pugh A	53 (38)	86 (62)	0.0062	0.592	1.327 (0.472-3.725)
Child-Pugh B/C	25 (62)	15 (38)
MELD	10 ± 3	8 ± 3	< 0.0011	0.082	1.177 (0.980-1.414)
Creatinine (mg/dL)	0.8 ± 0.3	0.9 ± 0.8	0.3441	-	-
Platelets (/nL)	104 ± 56	126 ± 64	0.0141	0.617	0.998 (0.992-1.005)
Albumin (g/L)	36.7 ± 5.2	39.9 ± 4.9	< 0.0011	0.057	0.928 (0.860-1.002)
Bilirubin (mg/dL)	1.6 ± 1.0	1.1 ± 0.8	< 0.0011	0.739	1.096 (0.638-1.883)

Data are expressed as n (%) or means ± SD (range). Baseline and follow-up data at 12 wk after the end of treatment was available for n = 179 patients.

¹t-test;

²Chi-square-test;

³Multivariable logistic regression.